Non-invasive delivery of nanoparticles to hair follicles: A perspective for transcutaneous immunization

Vaccine

Volumn 31, Issue 34, 2013, Pages 3442-3451

  Mittal, Ankit ^a   Raber, Anne S ^a   Schaefer, Ulrich F ^a   Weissmann, Sebastian ^c   Ebensen, Thomas ^c   Schulze, Kai ^c   Guzmán, Carlos A ^c   Lehr, Claus Michael ^a,b   Hansen, Steffi ^a,b  

^a SAARLAND UNIVERSITY   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

CD4+; CD8+; Chitosan; Drug delivery; Nanoparticle; Ovalbumin; PLGA; Transcutaneous immunization; Transfollicular immunization

Indexed keywords

CHITOSAN; ENDOGRADE; NANOPARTICLE; OVALBUMIN; POLYGLACTIN; POLYVINYL ALCOHOL; UNCLASSIFIED DRUG; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CULTURE MEDIUM; DENDRITIC CELL; FEMALE; HAIR FOLLICLE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SWINE; TRANSCUTANEOUS IMMUNIZATION;

CD4+; CD8+; CHITOSAN; DRUG DELIVERY; NANOPARTICLE; OVALBUMIN; PLGA; TRANSCUTANEOUS IMMUNIZATION; TRANSFOLLICULAR IMMUNIZATION;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTIGENS; CELL PROLIFERATION; CHITOSAN; DENDRITIC CELLS; FEMALE; HAIR FOLLICLE; IMMUNIZATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NANOPARTICLES; OVALBUMIN; POLYGLACTIN 910; SWINE; T-LYMPHOCYTES; VACCINES;

EID: 84880510462     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.12.048     Document Type: Article

References (57)

1. Glenn G.M., Taylor D.N., Li X., Frankel S., Montemarano A., Alving C.R. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat Med 2000, 6(December (12)):1403-1406.
2. Hansen S., Lehr C.M. Nanoparticles for transcutaneous vaccination. Microbiol Biotechnol 2012, 5(March (2)):156-167.
3. Combadiere B., Mahe B. Particle-based vaccines for transcutaneous vaccination. Comp Immunol Microb 2008, 31(March (2/3)):293-315.
4. Karande P., Mitragotri S. Transcutaneous immunization: an overview of advantages, disease targets, vaccines, and delivery technologies. Annu Rev Chem Biom Eng 2010, 1:175-201.
5. Glenn G.M., Kenney R.T. Mass vaccination: solutions in the skin. Curr Top Microbiol 2006, 304:247-268.
6. Schneider M., Stracke F., Hansen S., Schaefer U.F. Nanoparticles and their interactions with the dermal barrier. Dermatoendocrinology 2009, 1(July (4)):197-206.
7. Fan H., Lin Q., Morrissey G.R., Khavari P.A. Immunization via hair follicles by topical application of naked DNA to normal skin. Nat Biotechnol 1999, 17(September (9)):870-872.
8. Domashenko A., Gupta S., Cotsarelis G. Efficient delivery of transgenes to human hair follicle progenitor cells using topical lipoplex. Nat Biotechnol 2000, 18(April (4)):420-423.
9. Lademann J., Richter H., Teichmann A., Otberg N., Blume-Peytavi U., Luengo J., et al. Nanoparticles-an efficient carrier for drug delivery into the hair follicles. Eur J Pharm Biopharm 2007, 66(May (2)):159-164.
10. Shaker D.S., Sloat B.R., Le U.M., Lohr C.V., Yanasarn N., Fischer K.A., et al. Immunization by application of DNA vaccine onto a skin area wherein the hair follicles have been induced into anagen-onset stage. Mol Ther J Am Soc Gene Ther 2007 Nov, 15(11):2037-2043.
11. Yu Z., Chung W.G., Sloat B.R., Lohr C.V., Weiss R., Rodriguez B.L., et al. The extent of the uptake of plasmid into the skin determines the immune responses induced by a DNA vaccine applied topically onto the skin. J Pharm Pharmacol 2011 Feb, 63(2):199-205.
12. Weigmann H.J., Lademann J., Meffert H., Schaefer H., Sterry W. Determination of the horny layer profile by tape stripping in combination with optical spectroscopy in the visible range as a prerequisite to quantify percutaneous absorption. Skin Pharmacol Appl Skin Physiol 1999, 12(January-April (1/2)):34-45.
13. Blanco M.D., Alonso M.J. Development and characterization of protein-loaded poly(lactide-co-glycolide) nanospheres. Eur J Pharm Biopharm 1997, 43(3):287-294.
14. Schulze C., Schaefer U.F., Ruge C.A., Wohlleben W., Lehr C.M. Interaction of metal oxide nanoparticles with lung surfactant protein A. Eur J Pharm Biopharm 2011, 77(April 3):376-383.
15. Lademann J., Weigmann H.J., Schanzer S., Richter H., Audring H., Antoniou C., et al. Optical investigations to avoid the disturbing influences of furrows and wrinkles quantifying penetration of drugs and cosmetics into the skin by tape stripping. J Biomed Opt 2005, 10(September-October (5)):54015.
16. Weiss B., Schaefer U.F., Zapp J., Lamprecht A., Stallmach A., Lehr C.-M. Nanoparticles made of fluorescence-labelled poly(l-lactide-co-glycolide): preparation, stability, and biocompatibility. J Nanosci Nanotechnol 2006, 6(9-10):3048-3056. 2006.
17. Liard C., Munier S., Arias M., Joulin-Giet A., Bonduelle O., Duffy D., et al. Targeting of HIV-p24 particle-based vaccine into differential skin layers induces distinct arms of the immune responses. Vaccine 2011, 29(August 26 (37)):6379-6391.
18. Mahe B., Vogt A., Liard C., Duffy D., Abadie V., Bonduelle O., et al. Nanoparticle-based targeting of vaccine compounds to skin antigen-presenting cells by hair follicles and their transport in mice. J Invest Dermatol 2009, 129(May (5)):1156-1164.
19. Jacobi U., Engel K., Patzelt A., Worm M., Sterry W., Lademann J. Penetration of pollen proteins into the skin. Skin Pharmacol Physiol 2007, 20(6):297-304.
20. Taylor P.E., Jacobson K.W., House J.M., Glovsky M.M. Links between pollen, atopy and the asthma epidemic. Int Arch Allergy Immunol 2007, 144(2):162-170.
21. Streilein J.W., Lonsberry L.W., Bergstresser P.R. Depletion of epidermal langerhans cells and Ia immunogenicity from tape-stripped mouse skin. J Exp Med 1982, 155(March 1 (3)):863-871.
22. Gilliam A.C., Kremer I.B., Yoshida Y., Stevens S.R., Tootell E., Teunissen M.B., et al. The human hair follicle: a reservoir of CD40+ B7-deficient Langerhans cells that repopulate epidermis after UVB exposure. J Invest Dermatol 1998, 110(April 4):422-427.
23. Gupta R.K., Singh M., O'Hagan D.T. Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines. Adv Drug Deliver Rev 1998, 32(July (63)):225-246.
24. Amidi M., Mastrobattista E., Jiskoot W., Hennink W.E. Chitosan-based delivery systems for protein therapeutics and antigens. Adv Drug Deliver Rev 2010 Jan 31, 62(1):59-82.
25. Pai S.S., Tilton R.D., Przybycien T.M. Poly(ethylene glycol)-modified proteins: implications for poly(lactide-co-glycolide)-based microsphere delivery. AAPS J 2009, 11(March 1):88-98.
26. Taetz S., Nafee N., Beisner J., Piotrowska K., Baldes C., Murdter T.E., et al. The influence of chitosan content in cationic chitosan/PLGA nanoparticles on the delivery efficiency of antisense 2'-O-methyl-RNA directed against telomerase in lung cancer cells. Eur J Pharm Biopharm 2009, 72(June 2):358-369.
27. Mao S., Sun W., Kissel T. Chitosan-based formulations for delivery of DNA and siRNA. Adv Drug Deliver Rev 2010, 62(Jan 31 (1)):12-27.
28. Lehr C.-M., Bouwstra J.A., Schacht E.H., Junginger H.E. In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int J Pharm 1992, 78(1):43-48. 1992.
29. Bal S.M., Slutter B., van Riet E., Kruithof A.C., Ding Z., Kersten G.F., et al. Efficient induction of immune responses through intradermal vaccination with N-trimethyl chitosan containing antigen formulations. J Control Release 2010, 142(Mar 19 (3)):374-383.
30. Friede M., Aguado M.T. Need for new vaccine formulations and potential of particulate antigen and DNA delivery systems. Adv Drug Deliver Rev 2005, 57(Jan 10 (3)):325-331.
31. Men Y., Thomasin C., Merkle H.P., Gander B., Corradin G. A Single administration of tetanus toxoid in biodegradable microspheres Elicits T-Cell and antibody-responses similar or superior to those obtained with aluminum hydroxide. Vaccine 1995, 13(May 7):683-689.
32. Ogawa Y., Okada H., Heya T., Shimamoto T. Controlled release of Lhrh agonist, leuprolide acetate, from microcapsules-serum drug level profiles and pharmacological effects in animals. J Pharm Pharmacol 1989, 41(July (7)):439-444.
33. Riesz P., Kondo T. Free radical formation induced by ultrasound and its biological implications. Free Radic Biol Med 1992, 13(September (3)):247-270.
34. Determan A.S., Wilson J.H., Kipper M.J., Wannemuehler M.J., Narasimhan B. Protein stability in the presence of polymer degradation products: consequences for controlled release formulations. Biomaterials 2006, 27(June (17)):3312-3320.
35. Ye M.L., Kim S., Park K. Issues in long-term protein delivery using biodegradable microparticles. J Control Release 2010, 146(Sep 1 (2)):241-260.
36. Crotts G., Park T.G. Stability and release of bovine serum albumin encapsulated within poly(d,l-lactide-co-glycolide) microparticles. J Control Release 1997, 44(February 17 (2/3)):123-134.
37. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392(March 19 (6673)):245-252.
38. Maddur M.S., Vani J., Dimitrov J.D., Kithiganahalli N.Balaji, Lacroix-Desmazes S., Kaveri S.V., et al. Dendritic cells in autoimmune diseases. Open Arthritis J 2010, 3:1-7.
39. Lan Y.Y., Wang Z.L., Raimondi G., Wu W.H., Colvin B.L., De Creus A., et al. Alternatively activated dendritic cells preferentially secrete IL-10, expand Foxp3(+)CD4(+) T cells, and induce long-term organ allograft survival in combination with CTLA4-Ig. J Immunol 2006, 177(November 1 (9)):5868-5877.
40. Iyer S.S., Ghaffari A.A., Cheng G. Lipopolysaccharide-mediated IL-10 transcriptional regulation requires sequential induction of type I IFNs and IL-27 in macrophages. J Immunol 2010, 185(December 1 (11)):6599-6607.
41. Harush-Frenkel O., Debotton N., Benita S., Altschuler Y. Targeting of nanoparticles to the clathrin-mediated endocytic pathway. Biochem Biophys Res Commun 2007, 353(February 2 (1)):26-32.
42. Combadiere B., Vogt A., Mahe B., Costagliola D., Hadam S., Bonduelle O., et al. Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: a randomized phase I trial. PLoS ONE 2010, 5(5):e10818.
43. Keijzer C., Slutter B., van der Zee R., Jiskoot W., van Eden W., Broere F.P.L.G.A. PLGA-TMC and TMC-TPP nanoparticles differentially modulate the outcome of nasal vaccination by inducing tolerance or enhancing humoral immunity. PLoS ONE 2011, 6(11):e26684.
44. Slutter B., Plapied L., Fievez V., Sande M.A., des Rieux A., Schneider Y.J., et al. Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination. J Controlled Release Off J Controlled Release S 2009, 138(September 1 (2)):113-121.
45. Yoshida M., Babensee J.E. Molecular aspects of microparticle phagocytosis by dendritic cells. J Biomater Sci Polym Ed 2006, 17(8):893-907.
46. Fischer S., Uetz-von Allmen E., Waeckerle-Men Y., Groettrup M., Merkle H.P., Gander B. The preservation of phenotype and functionality of dendritic cells upon phagocytosis of polyelectrolyte-coated PLGA microparticles. Biomaterials 2007, 28(February (6)):994-1004.
47. Pape K.A., Kearney E.R., Khoruts A., Mondino A., Merica R., Chen Z-M., et al. Use of adoptive transfer of T-cell antigen-receptor-transgenic T cells for the study of T-cell activation in vivo. Immunol Rev 1997, 156(1):67-78.
48. Proksch E., Brasch J., Sterry W. Integrity of the permeability barrier regulates epidermal Langerhans cell density. Br J Dermatol 1996, 134(April (4)):630-638.
49. Mattheolabakis G., Lagoumintzis G., Panagi Z., Papadimitriou E., Partidos C.D., Avgoustakis K. Transcutaneous delivery of a nanoencapsulated antigen: induction of immune responses. Int J Pharm 2010, 385(January 29 (1/2)):187-193.
50. OECD. Guidance document for the conduct of skin absorption studies. OECD Series on Testing and Assessment. No. 28. Paris: Environment Directorate 2004.
51. Mangelsdorf S., Otberg N., Maibach H.I., Sinkgraven R., Sterry W., Lademann J. Ethnic variation in vellus hair follicle size and distribution. Skin Pharmacol Physiol 2006, 19(3):159-167.
52. Mangelsdorf S. Comparative evaluation of skin physiological parameters which inlfuence percutaneous penetration in different animal species 2006, Free University Berlin, Berlin.
53. Bronaugh R.L., Stewart R.F., Congdon E.R. Methods for in vitro percutaneous absorption studies. II. Animal models for human skin. Toxicol Appl Pharmacol 1982, 62(3):481-488. 1982.
54. Patzelt A., Richter H., Buettemeyer R., Huber H.J., Blume-Peytavi U., Sterry W., et al. Differential stripping demonstrates a significant reduction of the hair follicle reservoir in vitro compared to in vivo. Eur J Pharm Biopharm 2008, 70(September (1)):234-238.
55. Toll R., Jacobi U., Richter H., Lademann J., Schaefer H., Blume-Peytavi U. Penetration profile of microspheres in follicular targeting of terminal hair follicles. J Invest Dermatol 2004, 123(July (1)):168-176.
56. Patzelt A., Richter H., Knorr F., Schaefer U., Lehr C.M., Dahne L., et al. Selective follicular targeting by modification of the particle sizes. J Control Release 2011, 150(February 28 (1)):45-48.
57. Meidan V.M., Bonner M.C., Michniak B.B. Transfollicular drug delivery-is it a reality?. Int J Pharm 2005, 306(December 8 (1/2)):1-14.